Hyfe AI and ActiGraph Partner on AI-Powered Cough Detection
Hyfe has announced its partnership with ActiGraph to advance the use of AI-powered cough detection in clinical trials. Together, the companies are developing a new digital health tool to collect a combination of data. Hyfe’s Acoustic AI technology will be integrated into the new FDA-cleared ActiGraph LEAP™ to detect cough frequency and pattern to reveal an in-depth view of an individual’s health, an advancement in clinical research for chronic cough, COPD, congestive heart failure, asthma, and the many other conditions for which cough is an important symptom.
The ActiGraph LEAP contains collections of sensors that can continuously monitor sleep, mobility, heart rate and variability, oxygen saturation, blood pressure, and skin temperature in a single fit-for-purpose device. The addition of Hyfe’s cough data tracking supports the development of novel digital endpoints for improved pharmaceutical interventions for cough.
“We are thrilled to partner with ActiGraph and introduce our technology for integrating cough monitoring into their latest device,” said Joe Brew, co-founder and CEO of Hyfe. “The existing methods of assessing cough in clinical trials are antiquated, and through this collaboration, we share a unified vision of revolutionizing this space with advanced digital measures.”
“We are continuously looking for ways to advance the use of digital health technologies in clinical trials, and we are pleased to partner with the team at Hyfe to capture meaningful information about a key indicator of a patient's health: cough,” said Jeremy Wyatt, CEO of ActiGraph. “We see this as an incredibly valuable partnership that will give the clinical trial and pharmaceutical industries more comprehensive data than they’ve ever had before."
The partnership is part of ActiGraph’s Accelerant™ program, which aims to advance the use of digital health technologies in clinical development by simplifying CROs’ and technology vendors’ access to raw data streams.
Reference
Hyfe AI and ActiGraph Partner to Revolutionize Clinical Trials with AI-Powered Cough Detection. (2023, August 15). Hyfe AI.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
POETYK PsA-2 Trial Shows Efficacy of Sotyktu as an Oral Therapy for Psoriatic Arthritis
March 11th 2025Sotyktu (deucravacitinib) demonstrated significant efficacy in improving psoriatic arthritis symptoms compared to placebo in the Phase III POETYK PsA-2 trial, with a well-tolerated safety profile.
